Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study
SOLTI-1801 CDK-PREDICT 研究：在 HR+/HER2- 转移性乳腺癌患者中，一线 CDK4/6 抑制剂治疗进展后，根据 PAM50 内在亚型评估二线和三线治疗的真实世界无进展生存期
期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-026-07931-7
Tolosa, Pablo; García-Fructuoso, Isabel; Pascual, Tomás; Martínez-Sáez, Olga; Cejalvo, Juan Miguel; Servitja, Sonia; Fernández Abad, María; Benitez Fuentes, Javier David; Brasó-Maristany, Fara; Sanfeliu, Ester; Lema, Laura; Ruano, Yolanda; Parrilla, Lucía; Roncero, Ana María; Cobos, María Ángeles; Díaz, Irene; Centelles López, Karla Alicia; Sánchez-Bayona, Rodrigo; Alva, Manuel; Madariaga, Ainhoa; Villacampa, Guillermo; Salvador, Fernando; Sánchez-Belmonte, Agustín; Malumbres, Marcos; Prat, Aleix; Ciruelos, Eva
